JenaValve Technology reported that cardiovascular medical device industry veteran Stefan Schreck, Ph.D. has been named the Company's new chief technology officer.
In its release, the Company said that Dr. Schreck is a prolific inventor with more than 80 US patents and patent applications and brings to JenaValve more than 30 years of technology innovation and engineering leadership.
"Dr. Schreck is joining JenaValve at a time of great change and opportunity. Stefan's extensive domain experience and track record of innovations in the design of heart valves and related delivery systems makes him uniquely qualified to advance our pipeline and help position JenaValve as an important global TAVI player," said chief executive officer David J. Drachman. "We continue to expand our worldwide commercial footprint for our transapical TAVI system and are also investing significant resources in the development of our innovative transfemoral (TF) platform which we plan to launch in Europe during 2015. Our devices are the only TAVI products with CE Mark for both aortic stenosis and aortic insufficiency patients. Notably, our new steerable TF product has recently received FDA Fast Track designation."
Dr. Schreck was responsible for the development of surgical heart valve repair and replacement products including annuloplasty rings, and aortic and mitral bioprosthesis at Edwards Lifesciences before and after the spin-off from Baxter Healthcare. He also invented the first catheter based valve concepts for Edwards.
More Information and Complete Details:
((Comments on this story may be sent to firstname.lastname@example.org))